|
1
|
European Heart Rhythm Association;
European Association for Cardio-Thoracic Surgery. Camm AJ, Kirchhof
P, Lip GY, et al: Guidelines for the management of atrial
fibrillation: the Task Force for the Management of Atrial
Fibrillation of the European Society of Cardiology (ESC). Eur Heart
J. 31:2369–2429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen MS, Marrouche NF, Khaykin Y, et al:
Pulmonary vein isolation for the treatment of atrial fibrillation
in patients with impaired systolic function. J Am Coll Cardiol.
43:1004–1009. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khan MN, Jaïs P, Cummings J, et al:
PABA-CHF Investigators: Pulmonary-vein isolation for atrial
fibrillation in patients with heart failure. N Engl J Med.
359:1778–1785. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oral H, Scharf C, Chugh A, et al: Catheter
ablation for paroxysmal atrial fibrillation: segmental pulmonary
vein ostial ablation versus left atrial ablation. Circulation.
108:2355–2360. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iwasaki YK, Nishida K, Kato T and Nattel
S: Atrial fibrillation pathophysiology: implications for
management. Circulation. 124:2264–2274. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu X, Zhu X, Wang A, Fan H and Yuan H:
Effects of angiotensin-II receptor blockers on experimental
autoimmune myocarditis. Int J Cardiol. 137:282–288. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Y, Li WM, Gong YT, et al: The effects
of cilazapril and valsartan on the mRNA and protein expressions of
atrial calpains and atrial structural remodeling in atrial
fibrillation dogs. Basic Res Cardiol. 102:245–256. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Korantzopoulos P, Kolettis TM, Galaris D
and Goudevenos JA: The role of oxidative stress in the pathogenesis
and perpetuation of atrial fibrillation. Int J Cardiol.
115:135–143. 2007. View Article : Google Scholar
|
|
9
|
Kumagai K, Nakashima H, Urata H, et al:
Effects of angiotensin II type 1 receptor antagonist on electrical
and structural remodeling in atrial fibrillation. J Am Coll
Cardiol. 41:2197–2204. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tayebjee MH, Creta A, Moder S, Hunter RJ,
et al: Impact of angiotensin-converting enzyme-inhibitors and
angiotensin receptor blockers on long-term outcome of catheter
ablation for atrial fibrillation. Europace. 12:1537–1542. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
ONTARGET Investigators. Yusuf S, Teo KK,
Pogue J, et al: Telmisartan, ramipril, or both in patients at high
risk for vascular events. N Engl J Med. 358:1547–1559. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hunt SA, Abraham WT, Chin MH, et al: 2009
focused update incorporated into the ACC/AHA 2005 Guidelines for
the Diagnosis and Management of Heart Failure in Adults: a report
of the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines: developed in
collaboration with the International Society for Heart and Lung
Transplantation. Circulation. 119:e391–e479. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oakes RS, Badger TJ, Kholmovski EG, et al:
Detection and quantification of left atrial structural remodeling
with delayed-enhancement magnetic resonance imaging in patients
with atrial fibrillation. Circulation. 119:1758–1767. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Benjamin EJ, Levy D, Vaziri SM, et al:
Independent risk factors for atrial fibrillation in a
population-based cohort. The Framingham Heart Study. JAMA.
271:840–844. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hocini M, Sanders P, Jaïs P, et al:
Techniques for curative treatment of atrial fibrillation. J
Cardiovasc Electrophysiol. 15:1467–1471. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Verma A, Wazni OM, Marrouche NF, et al:
Pre-existent left atrial scarring in patients undergoing pulmonary
vein antrum isolation: an independent predictor of procedural
failure. J Am Coll Cardiol. 45:285–292. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lipman EW, Madsen N, Lin AC, et al:
Incidence and determinants of left atrial scar in patients with
paroxysmal and persistent atrial fibrillation undergoing catheter
ablation. Heart Rhythm. 2(Suppl): S122005. View Article : Google Scholar
|
|
18
|
Everett TH 4th, Li H, Mangrum JM, et al:
Electrical, morphological, and ultrastructural remodeling and
reverse remodeling in a canine model of chronic atrial
fibrillation. Circulation. 102:1454–1460. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dernellis J and Panaretou M: C-reactive
protein and paroxysmal atrial fibrillation: evidence of the
implication of an inflammatory process in paroxysmal atrial
fibrillation. Acta Cardiol. 56:375–380. 2001. View Article : Google Scholar
|
|
20
|
Cardin S, Li D, Thorin-Trescases N, et al:
Evolution of the atrial fibrillation substrate in experimental
congestive heart failure: angiotensin-dependent and -independent
pathways. Cardiovasc Res. 60:315–325. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ehrlich JR, Hohnloser SH and Nattel S:
Role of angiotensin system and effects of its inhibition in atrial
fibrillation: clinical and experimental evidence. Eur Heart J.
27:512–518. 2006. View Article : Google Scholar
|
|
22
|
Zhao J, Li J, Li W, et al: Effects of
spironolactone on atrial structural remodelling in a canine model
of atrial fibrillation produced by prolonged atrial pacing. Br J
Pharmacol. 159:1584–1594. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen YJ, Chen YC, Tai CT, et al:
Angiotensin II and angiotensin II receptor blocker modulate the
arrhythmogenic activity of pulmonary veins. Br J Pharmacol.
147:12–22. 2006. View Article : Google Scholar
|
|
24
|
López B, Querejeta R, Varo N, et al:
Usefulness of serum carboxy-terminal propeptide of procollagen type
I in assessment of the cardioreparative ability of antihypertensive
treatment in hypertensive patients. Circulation. 104:286–291. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Caballero R, Delpón E, Valenzuela C, et
al: Losartan and its metabolite E3174 modify cardiac delayed
rectifier K(+) currents. Circulation. 101:1199–1205. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Moreno I, Caballero R, González T, et al:
Effects of irbesartan on cloned potassium channels involved in
human cardiac repolarization. J Pharmacol Exp Ther. 304:862–873.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sestito A: Hypertension therapy and
cardiovascular protection. Effects of angiotensin II receptor block
with Valsartan. Eur Rev Med Pharmacol Sci. 15:1247–1255.
2011.PubMed/NCBI
|
|
28
|
Harada M, Luo X, Qi XY, et al: Transient
receptor potential canonical-3 channel-dependent fibroblast
regulation in atrial fibrillation. Circulation. 126:2051–2064.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao J, Wang X, Hang P, et al: Valsartan
inhibits transient receptor potential canonical-3 channel in canine
atrial fibrillation. Int J Cardiol. 168:4417–4418. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Parving HH, Lehnert H, Bröchner-Mortensen
J, et al: Irbesartan in Patients with Type 2 Diabetes and
Microalbuminuria Study Group: The effect of irbesartan on the
development of diabetic nephropathy in patients with type 2
diabetes. N Engl J Med. 345:870–878. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Madrid AH, Marín IM, Cervantes CE, et al:
Prevention of recurrences in patients with lone atrial
fibrillation. The dose-dependent effect of angiotensin II receptor
blockers. J Renin Angiotensin Aldosterone Syst. 5:114–120. 2004.
View Article : Google Scholar : PubMed/NCBI
|
